Chromic-P32 phosphate treatment of implanted pancreatic carcinoma: Mechanism involved

Table 2 Absorbed dose, rates of Pc-3 cell apoptosis and necrosis, percentages of Apo2.7 and caspase-3 positive expression (%) and Bcl-2/Bax value in different activity groups.

Group (n = 5)	Radioactivity(MBq)	Tumor absorbeddose (Gy)	Pc-3 cell apoptosisrate (%) rate	SNK	Pc-3 cell necrosis(%)	SNK	Apo2.7 positive (%)	Caspase-3positive (%)	Bcl-2/Bax
14	0	0.00±0.00	0.67±0.15	A	1.8±0.5	A	4.9±1.8	7.69±1.5	2.07±0.85
9	0.37	2.89±0.20	10.09±1.84	B	2.2±0.6	B	8.3±2.4	10.43±2.6	1.64±0.62
10	0.74	5.78±0.25	17.36±4.33	C	6.0±1.1	B	13.6±2.3	13.46±2.9	1.02±0.52
11	1.48	11.56±1.29	21.85±3.04	D	11.7±0.5	C	15.0±3.2	14.92±4.1	0.81±0.32
12	2.96	23.12±3.12	33.67±3.69	E	13.1±1.0	D	16.3±3.1	18.68±4.6	0.37±0.12
13	5.92	46.23±4.20	27.76±4.09	F	23.4±2.6	D	27.3±4.9	25.57±5.3	0.07±0.03

Variance analysis after conversion of tumor cell apoptosis and necrosis rate to square root: cell apoptosis rate, F = 178.12, P<0.001, statistical difference between groups; Cell necrosis rate, F = 249.27, P<0.001, statistical difference between groups, if the variance analysis of the mean Pc-3 apoptosis and necrosis rate showed statistical differences, Student–Newman–Keuls’ method was employed.